Cargando…
Complete remission after the first cycle of induction chemotherapy determines the clinical efficacy of relapse‐preventive immunotherapy in acute myeloid leukaemia
Autores principales: | Nilsson, Malin S., Hallner, Alexander, Brune, Mats, Nilsson, Staffan, Thorén, Fredrik B., Martner, Anna, Hellstrand, Kristoffer |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7027927/ https://www.ncbi.nlm.nih.gov/pubmed/31853942 http://dx.doi.org/10.1111/bjh.16320 |
Ejemplares similares
-
Immunotherapy with HDC/IL-2 may be clinically efficacious in acute myeloid leukemia of normal karyotype
por: Nilsson, Malin S., et al.
Publicado: (2019) -
Impact of NK Cell Activating Receptor Gene Variants on Receptor Expression and Outcome of Immunotherapy in Acute Myeloid Leukemia
por: Hussein, Brwa Ali, et al.
Publicado: (2021) -
Corrigendum: Impact of NK Cell Activating Receptor Gene Variants on Receptor Expression and Outcome of Immunotherapy in Acute Myeloid Leukemia
por: Hussein, Brwa Ali, et al.
Publicado: (2022) -
NK cell expression of natural cytotoxicity receptors may determine relapse risk in older AML patients undergoing immunotherapy for remission maintenance
por: Martner, Anna, et al.
Publicado: (2015) -
Role of regulatory T cells in acute myeloid leukemia patients undergoing relapse-preventive immunotherapy
por: Sander, Frida Ewald, et al.
Publicado: (2017)